# US 12,180,153 B2 · Method of treating ocular disorders with compounds found in Harderian gland secretions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,180,153 B2
- Document ID: US12180153B2
- Status: Granted
- Kind: B2
- Application number: 17/749,583
- Filed: 2022-05-20
- Published: 2022-09-01
- Granted: 2024-12-31
- Earliest claimed: 2013-11-20
- Assignees: RestorTears, LLC
- Applicants: RestorTears, LLC
- Inventors: Daniel M. Albert; Arthur S. Polans
- Web page: https://patentgrep.com/patent/US12180153B2

## CPC

- C07C 69/708: Ethers
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/225: Polycarboxylic acids
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- C07C 69/28: esterified with dihydroxylic compounds
- C07C 69/593: Dicarboxylic acid esters having only one carbon-to-carbon double bond
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to pharmaceutical compositions comprising compounds found in Harderian gland secretions, a method of treating dry eye in a human comprising ophthalmically administering an effective amount of a compound, e.g. a lipid compound, found in Harderian gland secretions, pharmaceutical compositions comprising said lipid compounds, as identified by characteristic chemical data and mass spectra of said lipid compounds, said lipid compound in essentially pure form, and an ophthalmic vehicle comprising a therapeutic agent and a compound present in the secretions of the Harderian gland, e.g. a lipid compound, found in the secretions of the Harderian gland, e.g. a rabbit Harderian gland.

## Claims

### Claim 1

A method of treating dry eye in a human in need thereof comprising opthalmically administering an effective amount of a compound having the formula:

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is formulated in an ophthalmically acceptable carrier.

### Claim 3 (depends on 2)

The method of claim 2, wherein the ophthalmically acceptable carrier comprises a component selected from the group consisting of an effective amount of a buffer component; an effective amount of a tonicity component; and an effective amount of a preservative component.

### Claim 4 (depends on 2)

The method of claim 2, wherein the ophthalmically acceptable carrier comprises a component selected from the group consisting of an effective amount of a buffer component and an effective amount of a tonicity component.

### Claim 5 (depends on 3)

The method of claim 3, wherein the ophthalmically acceptable carrier comprises a component selected from the group consisting of an effective amount of a buffer component; an effective amount of a tonicity component; and water.

### Claim 6 (depends on 1)

The method of claim 1, wherein said compound is administered in combination with an additional therapeutic agent.

### Claim 7 (depends on 6)

The method of claim 6, wherein the additional therapeutic agent is selected from the group consisting of: NMDA antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, immunosuppressives, antiparasitics, miotics, syrnpathomimetics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, adrenergic anesthetics, beta blockers, alpha-2-agonists, cycloplegics, prostaglandins, derivatives thereof and mixtures thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the compound is administered topically.